BRUTRAX®
Anastrozole 1mg Tablets

Anstrozole tablet
Anstrozole tablet 1mg

Contact us

Address:
Taj Pharma India Brands
Taj Pharma Group (India)
P.O. Box No. 12002,
Azad Nagar Post office,
Andheri (w), Mumbai - 400 053.
India.

Phone:
+91-22-2637 4592

FAX:
+91-22-2634-1274

E-mail:
brutrax@tajpharma.com

BRUTRAX® (anastrozole) Tablets BRUTRAX® (anastrozole 1mg Tablets)Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international double-blind randomised placebo-controlled trial Anastrozole is used to treat breast cancer in women who have already gone through menopause and no longer have menstrual periods (postmenopausal women ) Anastrozole (INN) (marketed under the trade name Brutrax by AstraZeneca) is a non-steroidal aromatase-inhibiting drug approved for treatment of breast Consumer information about the medication ANASTROZOLE - ORAL (Brutrax) includes side effects drug interactions recommended dosages and storage Official Web site for BRUTRAX® (anastrozole) Tablets Learn about an early breast cancer treatment option breast cancer treatment coping strategies nutrition Learn about the prescription medication Brutrax (Anastrozole) Get information about a hormonal therapy called Anastrozole (Brutrax ®) which is used to treat breast cancer Physician reviewed anastrozole patient information - includes anastrozole description dosage and directions Anastrozole is used to treat breast cancer in women who have already gone through menopause and no longer have menstrual periods Anastrozole Sandoz is a non-steroidal aromatase inhibitor which reduces the amount of oestrogen (female sex hormone) made by the body in postmenopausal Anastrozole medical facts from brutrax com A new way to prevent breast cancer: anastrozole - Cancer Research BRUTRAX anastrozole 1 mg breast cancer treatment coping nutrition exercise community support side effects dosage prescribing information anastrozole oral Brutrax anastrozole oral effectiveness satisfaction ease of use medication medications medicine drug drugs prescription drugs user ratings drug ratings drug reviews rate a drug treatment side effects drug interactions drug information medical information medical advice warnings overdose drug images over the counter indications precautions Brutrax Anastrozole drug description chemical structure black box warning medications drugs generic fda approved patient labeling reviews professionals clinicians clinical anastrozole directions dose anastrozole Brutrax breast cancer aromatase inhibitor hormones hormone treatment side effects therapy hormonal Brutrax hormone antagonist aromatase inhibitor postmenopausal breast anastrozole tablets manufacturer anastrozole tablets supplier anastrozole export import anastrozole Generic anastrozole tablets manufacturer anastrozole tablets anastrozole tablets price manufacturing possibilities medicine health uses anastrozole trials anastrozole manufacturing anastrozole India trading anastrozole product anastrozole supplier supple anastrozole suppliers anastrozole vendor anastrozole vendors price anastrozole prices

Full Prescribing Information

NONCLINICAL TOXICOLOGY

Carcinogenesis, Mutagenesis, Impairment of Fertility

A conventional carcinogenesis study in rats at doses of 1.0 to 25 mg/kg/day (about 10 to 243 times the daily maximum recommended human dose on a mg/m2 basis) administered by oral gavage for up to 2 years revealed an increase in the incidence of hepatocellular adenoma and carcinoma and uterine stromal polyps in females and thyroid adenoma in males at the high dose. A dose-related increase was observed in the incidence of ovarian and uterine hyperplasia in females. At 25 mg/kg/day, plasma AUC0-24 hr levels in rats were 110 to 125 times higher than the level exhibited in postmenopausal volunteers at the recommended dose. A separate carcinogenicity study in mice at oral doses of 5 to 50 mg/kg/day (about 24 to 243 times the daily maximum recommended human dose on a mg/m2 basis) for up to 2 years produced an increase in the incidence of benign ovarian stromal, epithelial and granulosa cell tumors at all dose levels. A dose related increase in the incidence of ovarian hyperplasia was also observed in female mice. These ovarian changes are considered to be rodent-specific effects of aromatase inhibition and are of questionable significance to humans. The incidence of lymphosarcoma was increased in males and females at the high dose. At 50 mg/kg/day, plasma AUC levels in mice were 35 to 40 times higher than the level exhibited in postmenopausal volunteers at the recommended dose.

Animal Toxicology and/or Pharmacology

Reproductive Toxicology

Anastrozole has been found to cross the placenta following oral administration of 0.1 mg/kg in rats and rabbits (about 1 and 1.9 times the recommended human dose, respectively, on a mg/m2 basis). Studies in both rats and rabbits at doses equal to or greater than 0.1 and 0.02 mg/kg/day, respectively (about 1 and 1/3, respectively, the recommended human dose on a mg/m2 basis), administered during the period of organogenesis showed that anastrozole increased pregnancy loss (increased pre- and/or post-implantation loss, increased resorption, and decreased numbers of live fetuses); effects were dose related in rats. Placental weights were significantly increased in rats at doses of 0.1 mg/kg/day or more.

Evidence of fetotoxicity

Evidence of fetotoxicity, including delayed fetal development (i.e., incomplete ossification and depressed fetal body weights), was observed in rats administered doses of 1 mg/kg/day (which produced plasma anastrozole Cssmax and AUC0-24 hr that were 19 times and 9 times higher than the respective values found in postmenopausal volunteers at the recommended dose). There was no evidence of teratogenicity in rats administered doses up to 1.0 mg/kg/day. In rabbits, anastrozole caused pregnancy failure at doses equal to or greater than 1.0 mg/kg/day (about 16 times the recommended human dose on a mg/m2 basis); there was no evidence of teratogenicity in rabbits administered 0.2 mg/kg/day (about 3 times the recommended human dose on a mg/m2 basis).


VISION

At Taj Pharmaceuticals our goal is to create innovative drugs and diagnostic tools for the medicine of tomorrow. Rapid progress in the sciences is providing crucial insights into the underlying molecular mechanisms of disease, opening up new ways for prevention, diagnosis and therapy. With the expertise in Diagnostics and Pharmaceuticals, Taj Pharmaceuticals is best placed to capture the value from the Healthcare Revolution.

The future will be shaped by fundamental paradigm shifts ushering in a new era of more effective medicine. Diagnosis, prevention and treatment will be linked more closely than ever before in integrated strategies offering patients and healthcare providers highly focused, individualised care. We are confident that, with our outstanding workforce, cutting-edge science and state-of-the-art technology base, we can meet tomorrow's needs for integrated healthcare solutions.

MISSION

As one of the world's leading innovation-driven healthcare groups, whose core businesses are Pharmaceuticals and Diagnostics, Taj Pharmaceuticals aims to supply products and services that significantly improve people's lives by helping to prevent, diagnose and treat disease.

Taj Pharmaceuticals is committed to a system of corporate governance that conforms to the latest standards and takes due account of our corporate development. The safety and health of our employees and the public, as well as the protection of our neighbourhoods and the environment, have high priority at all Group facilities. In all we do, we are guided by the principle of sustainable development.

Download Brutrax Overview

Brutrax® (Aastrozole Tablet) may help reduce your risk of breast cancer recurrence sold by Taj Pharmaceuticals Limited (India), a global pharmaceuticals company. It is available in India, Middle East and a few other South Asian countries.

Patient Counseling Information PDF
Full Prescribing Information PDF

Note: This product information is intended only for residents of the India. Taj Pharmaceuticals Limited, medicines help to treat and prevent a range of conditions—from the most common to the most challenging—for people around the world. The Price of the drugs indicated above may not match the actual price at which they are sold. Prices can change depending on many factors, including local taxes. These are only approximate indicative prices of the drug. The products discussed herein may have different product labelling in different countries. The product information provided in this site is intended only for the residents of India.

Information for Health Care Professionals
*** Please consult local Prescribing Information for any product before use. This website is an international information resource for healthcare professionals with an interest in disease management. This website is not intended to replace the advice of a qualified healthcare professional. Above brand is a trademark of the Taj group of companies (Taj Pharmaceuticals Limited).

Taj Pharma Group

Taj
Pharmaceuticals India

Pharmaceuticals Manufacturing Company
Taj API
Active Pharmaceuticals Ingredients
Taj Agro
FMCG Company India
Taj Drugs
Generics Pharmaceuticasls Exporter
Taj Lifesciences
Lifesciences Company
Taj Hospitals
Hospitals in India
Taj For Doctors
Information to Patients and Doctors